Stabilis Noms commerciaux Aristin C Baycip Ciflox Ciphin Ciplox Ciprinol Cipro Ciprobay Cipromed Ciproxan Ciproxin Ciproxine Citeral Estecina Ladinin Nafloxin Proxacin Topistin Truoxin Grèce France Tchéquie Tchéquie Croatie, Pologne, Tchéquie Canada, Etats Unis d Amérique, Turquie Croatie, Hongrie, Slovénie, Tchéquie Croatie Japon Autriche, Grande Bretagne, Grèce, Italie, Suède, Suisse, Turquie Belgique Croatie Espagne Grèce Grèce Pologne Grèce Irlande Stabilité des solutions? mg/ml 25 C 90 666? mg/ml 5 C 90 666 1 mg/ml 2-8 C 30 3231 1 mg/ml 21-24 C 30 3231 1 mg/ml 29-31 C 30 3231 1,5 mg/ml 25 C 2 mg/ml 2-8 C 30 3231 2 mg/ml 21-24 C 30 3231 2 mg/ml 29-31 C 30 3231 www.stabilis.org - 07/03/2017 10:44 - Page 1
0,025 mg/ml 20 C 42 2368 0,025 mg/ml 37 C 42 2368 0,025 mg/ml 4 C 42 2368 5 & 20 mg/ml 25 C 30 604 5 & 20 mg/ml 4 C 90 604 4 mg/ml 23 C 7 1614 4 mg/ml 4 C 30 1614 Stabilité en mélange 1,5 mg/ml 25 C 1,5 mg/ml 25 C 1,5 mg/ml 25 C 1,5 mg/ml 25 C 1,5 mg/ml 4 C 1,5 mg/ml 4 C 1,5 mg/ml 4 C 1,5 mg/ml 4 C 4 mg/ml 23 C 4 mg/ml 4 C Gentamicin sulfate : 1 mg/ml Tobramycin sulfate : 1 mg/ml Amikacin sulfate : 1,5 mg/ml Metronidazole : 4 mg/ml Gentamicin sulfate : 1 mg/ml Tobramycin sulfate : 1 mg/ml Metronidazole : 4 mg/ml Amikacin sulfate : 1,5 mg/ml Linezolid : 2 mg/ml Linezolid : 2 mg/ml 7 1668 24 1668 Facteur influençant la stabilité 948 3475 301 [ 400 mg/ml ] 14 500 www.stabilis.org - 07/03/2017 10:44 - Page 2
Incompatibilités : 1.5 mg/ml Aminophylline : 1.2 mg/ml Aminophylline : 2 mg/ml Amoxicillin sodium : 10 mg/ml Amoxicillin sodium Amoxicillin sodium / clavulanic acid : 12 mg/ml Amoxicillin sodium / clavulanic acid Amphotericin B : 0.1 mg/ml : 1 mg/ml Amphotericin B liposomale : 0.83 mg/ml : 2.6 mg/ml Ampicillin sodium : 20 mg/ml Ampicillin sodium Ampicillin sodium - sulbactam sodium Ampicillin sodium - sulbactam sodium Ampicillin sodium - sulbactam sodium : 30 mg/ml Azithromycine : 2 mg/ml Ceftazidime : 20 mg/ml Ceftobiprole : 2 mg/ml : 1 mg/ml Ceftobiprole : 2 mg/ml Cefuroxime sodium : 30 mg/ml Clindamycin phosphate : 1.5 mg/ml Clindamycin phosphate : 7 mg/ml 434 3475 1357 1357 921 1392 1500 1800 2269 14 301 2269 3526 434 www.stabilis.org - 07/03/2017 10:44 - Page 3
Cloxacillin sodium Cloxacillin sodium : 100 mg/ml Flucloxacillin sodium : 10 mg/ml Furosemide : 10 mg/ml Furosemide : 5 mg/ml : 0,2 & 1 mg/ml Heparin sodium : 10 & 100 UI/ml Heparin sodium : 10 mg/ml Heparin sodium : 5000 UI/ml Heparin sodium : 10 >> 1000 UI/ml Heparin sodium : 10 UI/ml Heparin sodium Heparin sodium Heparin sodium : 100 UI/ml Hydrocortisone sodium succinate : 50 mg/ml Lansoprazole : 0.55 mg/ml Magnesium sulfate Meropenem Methylprednisolone sodium succinate : 62 mg/ml Metronidazole : 5 mg/ml Nafcillin sodium Oxacillin sodium Pantoprazole sodium Pemetrexed disodium : 20 mg/ml Penicillin G potassium Penicillin G sodium Phenytoin sodium : 50 mg/ml 3012 1357 289 2057 3540 1760 289 1393 2129 1625 3475 2090 1953 www.stabilis.org - 07/03/2017 10:44 - Page 4
Piperacillin sodium Piperacillin sodium : 40 mg/ml Piperacillin sodium / tazobactam Propofol Sodium bicarbonate : 10 mg/ml Sodium bicarbonate : 1 & 2 mg/ml Sodium bicarbonate Sodium bicarbonate : 4 mg/ml Teicoplanine : 60 mg/ml Thiopental sodium : 25 mg/ml Ticarcillin / clavulanic acid : 30 mg/ml Ticarcillin / clavulanic acid 660 269 14 289 3767 Voie d administration Bibliographie Type Source 14 Revue Gilbert DL, Trissel LA, Martinez JF. Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1193-1195. 269 Revue Trissel LA. Concentration-dependent precipitation of sodium bicarbonate with ciprofloxacin lactate. Am J Health-Syst Pharm 1996 ; 53: 84-85. Revue Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255. Revue Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962. 289 Revue Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707. www.stabilis.org - 07/03/2017 10:44 - Page 5
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. 434 Revue Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171. 500 Revue Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911. 604 Laboratoire Stabilité des médicaments dans l'intermate SV50, 100, 200 Baxter 1998 660 Revue Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. 666 Revue Mathew M, Das Gupta V, Zerai T. Stability of ciprofloxacin in 5% dextrose and normal saline injections. J Clin Pharm Ther 1994 ; 19: 261-262. 921 Revue Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. 948 Revue Tiefenbacher EM, Haen E, Przybilla B, Kurz H. Photodegradation of some quinolones used as antimicrobial therapeutics. J Pharm Sci 1994 ; 83: 463-467. 1357 Revue Janknegt R, Schrouff GGM, Hooymans PM, Hermens WJHH, Lohman JJHM. Quinolones and penicillins incompatibility. Ann Pharmacotherapy 1989 ; 23: 91-92. 1392 Revue Lewis GM, Donnelly RF. Ampicillin and ciprofloxacin incompatibility. Can J Hosp Pharm 1999 ; 52: 90. 1393 Revue Lyall D, Blythe J. infusion. Pharm J 1987 ; 238: 290. 1500 Revue Melonakos TK. Ciprofloxacin-ampicillin sulbactam incompatibility. Ann Pharmacotherapy 1996 ; 30: 87. 1614 Revue Trissel LA, Xu QA, Zhang Y, Saenz CA, Ingram DS. Stability of ciprofloxacin and vancomycin hydrochloride in autodose infusion system bags. Hosp Pharm 2001 ; 36: 1170-1173. 1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. 1668 Revue Zhang Y, Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three quinolone antibiotics. Ann Pharmacotherapy 2000 ; 34: 996-1001. 1760 Revue Vercaigne LM, Sitar DS, Penner B, Bernstein K, Wang GQ, Burczynski FJ. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 2000 ; 20: 394-399. 1800 Revue Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855. www.stabilis.org - 07/03/2017 10:44 - Page 6
1953 Revue Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. 2057 Revue Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003 ; 51: 849-855. 2090 Revue Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. 2129 Revue Vercaigne LM, Sitar DS, Penner SB, Bernstein K, Burczynski FJ. Antibiotic-heparin lock: In vitro antibiotic stability combined with heparin in an central venous catheter. Pharmacotherapy 2000 ; 20, 4: 394-399. 2269 Revue Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. 2368 Revue Mawhinney WM, Adair CG, Gorman SP, McClurg B. Stability of ciprofloxacin in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 2956-2959. 3012 Revue Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. 3231 Revue Donnelly RF. Stability of Ciprofloxacin in Polyvinylchloride Minibags. Can J Hosp Pharm 2011 ; 64, 4 : 252-256. 3475 Revue Chen L.Y, Chen J, Waters V, Boodhan S. Incompatibility of ciprofloxacin and meropenem injections. Am J Health-Syst Pharm 2013 ;70:1966-1970. 3526 Laboratoire Clindamycin (Dalacin ) - Summary of Product Characteristics Pharmacia 2010 Laboratoire Ciprofloxacin Summary of Product Characteristics Hospira 2013 3540 Laboratoire Heparin sodium - Summary of Product Characteristics. Wockhardt 2010 3767 Revue Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. www.stabilis.org - 07/03/2017 10:44 - Page 7
Dictionnaire Antibiotique Injectable Noms commerciaux Stabilité des solutions Contenant Molécule Concentration Température Conservation Heure Biosimilaire Données conflictuelles Bibliographie Polyvinyl chlorure NaCl 0,9% ou glucose 5% Non précisée Jour A l abri de la lumière Lumière Heure Dianéal PD1 1.36% glucose (Baxter) Elastomère Ethylène vinyl acétate Chlorure de sodium 0,9% Stabilité en mélange Solvant Molécule Polyolefine Aucun Facteur influençant la stabilité Provoque Dégradation Nutrition parentérale (mélange binaire) NaHCO3 Précipitation Incompatibilités Glucose 5% Ringer lactate Voie d administration Perfusion intraveineuse Bibliographie Dictionnaire www.stabilis.org - 07/03/2017 10:44 - Page 8